The company is currently testing whether its engineered antibody or “Humaneered” technology developed over two decades can catapult the company to a leading role in the scramble to conquer COVID-19.
Under the agreement, Covance will join Tempus’ TIME Trial Network, a data-driven approach that aims to improve the efficiency of clinical trials recruitment, design, and launch.
The company will expand its health benefits management offerings, as well as make investments in data analytics and innovative health tech
An exclusive Clinical OMICs conversation with the director of Genomes2People, Robert Green, M.D., MPH.
If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark...
The study could signal a potential treatment breakthrough for patients with this form of breast cancer, which disproportionately affects and tends to develop more aggressively in black women.
GenapSys’ sequencing system is about the size of an iPad, costs under $10,000, and is based on a proprietary direct electronic sequencing chip, which is intended to eliminate the need for cumbersome equipment.
The research indicated that T cell responses generated by natural exposure to, or infection with, SARS-CoV-2 may be a significant immune component to the prevention of recurrent episodes of severe disease.
The new partnerships are intended to bolster Thermo Fisher's Precision Medicine Science Center's mission of creating standardized workflows with pharma and academic partners, with the goal of enhancing precision medicine by streamlining the transition from biomarker research to clinical implementation.
Sponsor: IlluminaIn this Clinical OMICs KEYNOTE webinar, sponsored by Illumina, we are delighted to host two true pioneers of clinical genome sequencing, bioinformatician Dr. Liz Worthey and geneticist Dr. Howard Jacob, who will reflect on a decade of progress in clinical genome analysis and discuss the future challenges confronting the field.